Kancera AB (OSTO:KAN) Preferred Dividends : kr0.00 Mil (TTM As of Sep. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Kancera AB Preferred Dividends?

Preferred dividend is a dividend that is accrued and paid on a company's preferred shares. Kancera AB's preferred dividends for the three months ended in Sep. 2024 was kr0.00 Mil. Its preferred dividends for the trailing twelve months (TTM) ended in Sep. 2024 was kr0.00 Mil.

Kancera AB Preferred Dividends Historical Data

The historical data trend for Kancera AB's Preferred Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kancera AB Preferred Dividends Chart

Kancera AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Preferred Dividends

Get a 7-Day Free Trial

Kancera AB Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Preferred Dividends	Get a 7-Day Free Trial															-	-	-	-	-

Kancera AB Preferred Dividends Calculation

A dividend that is accrued and paid on a company's preferred shares.

Kancera AB (OSTO:KAN) Preferred Dividends Explanation

In the event that a company is unable to pay all dividends, claims to preferred dividends take precedence over claims to dividends that are paid on common shares.

Preferred Dividends for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

Kancera AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kancera AB (OSTO:KAN) » Definitions » Preferred Dividends

Comparable Companies

Traded in Other Exchanges

N/A

Address

Karolinska Institutet Science Park, Banvaktsvagen 22, Solna, SWE, 171 48

Website

http://www.kancera.com

Kancera AB develops drugs that counteract damage in acute and chronic inflammation. The fractalkin blockers KAND567 and KAND145 are developed to effectively counteract hyperinflamation in various disease states and thereby protect vital organs in conjunction with myocardial infarction and severe viral infections. Kancera is planning two phase II clinical trials, in covid-19 and in cardiac patients. The company conducts research and development within the Karolinska Institute Science Park in Stockholm.

Kancera AB Headlines

No Headlines